
Alx Oncology Holdings is a biotechnology business based in the US. Alx Oncology Holdings shares (ALXO) are listed on the NASDAQ and all prices are listed in US Dollars. Alx Oncology Holdings employs 44 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Alx Oncology Holdings
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ALXO – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Alx Oncology Holdings stock price (NASDAQ: ALXO)
Use our graph to track the performance of ALXO stocks over time.Alx Oncology Holdings shares at a glance
Latest market close | $8.10 |
---|---|
52-week range | $5.82 - $81.19 |
50-day moving average | $10.16 |
200-day moving average | $28.77 |
Wall St. target price | $43.25 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.32 |
Buy Alx Oncology Holdings shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Alx Oncology Holdings stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Alx Oncology Holdings price performance over time
Historical closes compared with the close of $8.1 from 2022-06-29
1 week (2022-06-23) | 8.72% |
---|---|
1 month (2022-05-27) | 0.62% |
3 months (2022-03-26) | N/A |
6 months (2021-12-30) | -63.06% |
1 year (2021-06-30) | -85.19% |
---|---|
2 years (2020-06-26) | N/A |
3 years (2019-06-26) | N/A |
5 years (2017-06-26) | N/A |
Alx Oncology Holdings financials
Gross profit TTM | $107,000 |
---|---|
Return on assets TTM | -14.77% |
Return on equity TTM | -24.62% |
Profit margin | 0% |
Book value | $8.45 |
Market capitalisation | $303.1 million |
TTM: trailing 12 months
Alx Oncology Holdings share dividends
We're not expecting Alx Oncology Holdings to pay a dividend over the next 12 months.
Alx Oncology Holdings overview
ALX Oncology Holdings Inc. , a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc.
Alx Oncology Holdings in the news
ALX's stock is up 11% after getting orphan-drug designation for cancer drug
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia
Frequently asked questions
What percentage of Alx Oncology Holdings is owned by insiders or institutions?Currently 13.709% of Alx Oncology Holdings shares are held by insiders and 88.051% by institutions. How many people work for Alx Oncology Holdings ?
Latest data suggests 44 work at Alx Oncology Holdings . When does the fiscal year end for Alx Oncology Holdings ?
Alx Oncology Holdings 's fiscal year ends in December. Where is Alx Oncology Holdings based?
Alx Oncology Holdings 's address is: 323 Allerton Avenue, South San Francisco, CA, United States, 94080 What is Alx Oncology Holdings 's ISIN number?
Alx Oncology Holdings 's international securities identification number is: US00166B1052
More guides on Finder
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert